Safety and Efficacy of Ultra-Rush Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen
Primary Purpose
Asthma
Status
Completed
Phase
Phase 4
Locations
Poland
Study Type
Interventional
Intervention
Staloral 300
placebo
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring Asthma, Sublingual immunotherapy, Children
Eligibility Criteria
Inclusion Criteria:
- patients allergic to grasses pollen
- patients with bronchial asthma
- patients with controlled asthma
- patients who were qualified for immunotherapy and gave written informed consent for immunotherapy
Exclusion Criteria:
- patients allergic for other perennial and seasonal allergens
- patients with other chronic diseases that either put the patient at risk when participating in the study or could influence the results of the study or the patient's ability to participate in the study as judged by the investigator
Sites / Locations
- Department of Pediatrics and Allergy, Medical University of Lodz, Poland
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
1
2
Arm Description
Outcomes
Primary Outcome Measures
clinical symptoms, reliever drugs usage, controller medication usage, lung function
Secondary Outcome Measures
chosen markers of inflammation (specific IgE, IgG4, eosinophils)
skin prick test, specific nasal provocation test with grass pollen allergen
bronchial hyperreactivity with methacholine
Full Information
NCT ID
NCT00518518
First Posted
August 17, 2007
Last Updated
May 14, 2009
Sponsor
Medical University of Lodz
1. Study Identification
Unique Protocol Identification Number
NCT00518518
Brief Title
Safety and Efficacy of Ultra-Rush Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen
Official Title
Safety and Efficacy of Ultra-Rush High-Dose Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen - Prospective, Randomized, Placebo Controlled Study.
Study Type
Interventional
2. Study Status
Record Verification Date
May 2009
Overall Recruitment Status
Completed
Study Start Date
March 2006 (undefined)
Primary Completion Date
November 2008 (Actual)
Study Completion Date
November 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Medical University of Lodz
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of the study is to assess the safety and efficacy of sublingual immunotherapy applied preseasonal and seasonal in ultra-rush scheme in children with bronchial asthma allergic to grass pollen. The investigators will assess clinical symptoms, reliever drugs usage, lung function, chosen markers of allergic inflammation, bronchial hyperreactivity with methacholine, and presence and type of allergy after two years of sublingual immunotherapy (SLIT) in children with asthma.
Detailed Description
Specific immunotherapy is the only causal treatment method of atopic diseases including bronchial asthma in children. Sublingual immunotherapy seems to be the most promising alternative to traditional specific subcutaneous injection immunotherapy.
The aim of the study is to assess the safety and efficacy of sublingual immunotherapy applied preseasonal and seasonal in ultra-rush scheme in children with bronchial asthma allergic to grass pollen. We will assess clinical symptoms, reliever drugs usage, lung function, chosen markers of allergic inflammation, bronchial hyperreactivity with methacholine, and presence and type of allergy after two years of SLIT in children with asthma.
After two years the study will be unblinded, all the children will be given grass pollen allergen extract for a year.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, Sublingual immunotherapy, Children
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Title
2
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Staloral 300
Intervention Description
Staloral 300
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
placebo
Primary Outcome Measure Information:
Title
clinical symptoms, reliever drugs usage, controller medication usage, lung function
Time Frame
all visits
Secondary Outcome Measure Information:
Title
chosen markers of inflammation (specific IgE, IgG4, eosinophils)
Time Frame
1 month after baseline visit (second visit), after 5 months (fifth visit), after 18 months (ninth visit), after 30 months (thirteenth visit)
Title
skin prick test, specific nasal provocation test with grass pollen allergen
Time Frame
baseline visit, after 24 months (tenth visit), after 36 months (fourteenth visit)
Title
bronchial hyperreactivity with methacholine
Time Frame
after 5 months (fifth visit), after 18 months (sixth visit), after 30 months (thirteenth visit)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients allergic to grasses pollen
patients with bronchial asthma
patients with controlled asthma
patients who were qualified for immunotherapy and gave written informed consent for immunotherapy
Exclusion Criteria:
patients allergic for other perennial and seasonal allergens
patients with other chronic diseases that either put the patient at risk when participating in the study or could influence the results of the study or the patient's ability to participate in the study as judged by the investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joanna Kaczmarek, MD
Organizational Affiliation
Department of Pediatrics and Allergy, Medical University of Lodz, Poland
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Iwona Stelmach, MD, PhD, Prof
Organizational Affiliation
Department of Pediatrics and Allergy, Medical University of Lodz, Poland
Official's Role
Study Chair
Facility Information:
Facility Name
Department of Pediatrics and Allergy, Medical University of Lodz, Poland
City
Lodz
ZIP/Postal Code
93-513
Country
Poland
12. IPD Sharing Statement
Citations:
PubMed Identifier
19134016
Citation
Stelmach I, Kaczmarek-Wozniak J, Majak P, Olszowiec-Chlebna M, Jerzynska J. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy. 2009 Mar;39(3):401-8. doi: 10.1111/j.1365-2222.2008.03159.x. Epub 2008 Dec 23.
Results Reference
result
Learn more about this trial
Safety and Efficacy of Ultra-Rush Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen
We'll reach out to this number within 24 hrs